SSHA

Society of Sexual Health Advisers

Unite the union
  • About us
    • JOIN SSHA
    • Code of Professional Conduct
    • National Organising Professional Committee
    • National Organising Professional Committee Structure
    • Constitution and Rules
    • Council Reports
    • NPC ACCESS ONLY
  • News
  • Regions
    • London
    • North East, Yorkshire & Humberside
    • Ireland
    • Scotland
    • South West
    • East Midlands – VACANT
    • North West
    • South East
    • Wales
    • West Midlands
  • Resources
    • I Want To Be A Health Adviser
    • SSHA Manual
    • Conference Presentations
    • Competency Framework for Sexual Health Advisers
    • WeSSI: West Sussex Sexual Health Structured Interview
    • Research
    • Unite – Union
    • Publications
  • Jobs
    • Current Jobs
    • Sample Job Descriptions
  • Links
Home ยป Change to recommended regimen for post-exposure prophylaxis (PEP)

Change to recommended regimen for post-exposure prophylaxis (PEP)

September 9, 2014 By SSHA Leave a Comment

Expert Advisory Group on AIDS

Providing expert scientific advice on HIV

Change to recommended regimen for post-exposure prophylaxis (PEP)

EAGA was asked to review its recommended regimen for occupational post-exposure prophylaxis (PEP) in light of new evidence. When the PEP regimen was last changed, it was agreed that consistency should be maintained with the recommended regimen for PEP following sexual exposure (PEPSE).

Recognising that

  1. some PEP starter packs include domperidone1 as an anti-emetic to counteract side effects associated with the protease inhibitor (Kaletra) component of PEP;
  2. domperidone is now contra-indicated for use with boosted protease inhibitors (such as Kaletra) because of the risk of cardiac adverse events due to QT interval prolongation [1];
  3. the integrase inhibitor, raltegravir, can be stored at ambient temperature and is better tolerated when used as PEP than combinations including a ritonavir-boosted protease inhibitor [2], while having equal efficacy in suppressing viral replication in infected individuals [3,4].

EAGA recommends that

  1. PEP starter packs that include domperidone should have domperidone removed before being issued. Prescribers need to be aware of the interactions between domperidone and Kaletra and prescribe appropriate alternative anti-emetics if continuing to use Truvada/Kaletra e.g. while using up existing stocks of PEP starter packs.
  2. Until such time as the PEP/PEPSE guidelines have been systematically reviewed and updated, the preferred first-line regimen for PEP (for occupational and non-occupational use) is Raltegravir/Truvada for 28 days.

One Truvada tablet (245mg tenofovir disoproxil (as fumarate) and 200mg emtricitabine (FTC)) once a day

plus

One Raltegravir tablet (400mg) twice a day

The reasons for this choice include

  1. No significant safety issues with this combination from extensive testing in HIV-infected patients [3].
  2. Raltegravir is better tolerated than Kaletra, so switching is likely to improve adherence, and hence efficacy, of PEP.
  3. There are fewer drug interactions with integrase inhibitors than with other classes of antiretroviral agent.
  4. Raltegravir is stable for at least 1 year at room temperature2,

Reference

  1. MHRA. Domperidone: risks of cardiac side effects – indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. Drug Safety Update volume 7 issue 10, May 2014: A1.
  2. Mayer KH et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59: 354-9.
  3. Ridler SA et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
  4. Gotuzzo E et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr 2012; 61: 73-7.

Download

  • Original document

Filed Under: Latest SSHA News Tagged With: cardiac adverse events, domperidone, eaga, emtricitabine, FTC, fumerate, integrase inhibitor, kaletra, mayer, mhra, pep, pepse, post exposure prophylaxis, protease inhibitor, QT, raltegravir, ritonavir, side effects, tenofovir disoproxil, tenofvoir, truvada

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About SSHA

The Society of Sexual Health Advisers (SSHA) is a UK national organisation with approximately 300 members out of an estimated 350 sexual health advisers in the country. It provides an opportunity for members to meet and work towards further professional development.

Recent Posts

  • Helping People to Reduce Sexual Health Risk: A Motivational Interviewing Approach February 28, 2023

Useful Links

  • BASHH
  • HPV Action
  • NAM
  • Public Health England
  • Public Health Scotland
  • Terence Higgins Trust
  • UNITE the Union

Copyright © 2023 · SSHA - Society of Sexual Health Advisers

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT